This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP) CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.

Provided treatments

  • Drug: Dasatinib
  • Drug: BMS-833923

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01357655. The sponsor of the trial is Bristol-Myers Squibb and it is looking for 70 volunteers for the current phase.
Official trial title:
An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).